2015 OPSC Annual Convention. syllabus. February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California
|
|
- Linda Richard
- 5 years ago
- Views:
Transcription
1 2015 OPSC Annual Convention syllabus February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California
2 SUNDAY, FEBRUARY 8, 2015: 10:00am - 11:00am Primary Care of the HIV Patient Presented by Jim Lee, DO, AAHIVS
3 PRESENTATION Learning Objectives and Self ASSESSMENT questions LEARNING OBJECTIVES 1. Become aware of the basic issues of HIV 2. Learn how to identify HIV patients 3. Learn about testing for HIV 4. Become knowledgeable about HIV treatment 5. Learn how to maintain good health in the HIV patient 6. Learn what is not known about HIV care. SELF ASSESSMENT QUESTIONS 1. Patients who should be tested for HIV include: a. Homosexuals b. IV drug users c. 56 year old women d. all patients in their 20s e. anyone 13 to 64 years of age f. all of the above 2. The rate of new infection has decreased in the following group: a. 20 year olds b. IV drug users c. Hispanic women d. Black men e. MSM 3. Pre Exposure Prophylaxis should be not be used by this group: a. MSM b. disconcordant couples c. IV drug users d. HIV positive persons e. all the above 4. The Acute Anti Retroviral Syndrome does not include this finding: a. skin rash b. headache c. lymphadenopathy d. testicular pain e. anorexia 5. Initial treatment of the HIV positive patient should begin: a. at age 25 b. when Tcells are less than 350 c. when viral load is 50 + d. when patient is symptomatic e. immediately 6. The most recommended initial treatment regimens include: a. 2 nnrtis b. 2 Protease inhibitors c. 2 Integrase inhibitors d. only nnrtis e. Any of the above 7. The best way to find out if a drug is going to work is to do the following test: a. Chemistry panel b. HIV RNA PCR Quantitative c. Western Blot d. Elisa e. Phenosense GT plus Integrase OPSC s 54th Annual Convention and Exposition Syllabus 1148
4 OPSC s 54th Annual Convention and Exposition Syllabus 1149
5 Primary Care of HIV Patient well, one way to do it. OPSC s 54th Annual Convention and Exposition Syllabus 1150
6 Current Epidemiology US: 1.2 Million HIV positive persons 14% are unaware There are 50,000 new cases of HIV in the US each year. Highest rate in MSM. California: 120,000 HIV positive persons STDs Rate two fold higher among HIV positive MSM vs negative HIV in drug users. Decreased 80% since the late 1980s. Racial differences. 7.8 to 20 times higher in blacks, 2.8 x higher in Latinos. OPSC s 54th Annual Convention and Exposition Syllabus 1151
7 Whom to evaluate All persons 13 to 64 should be screened every year for HIV infection. Testing mechanisms HIV Elisa Western Blot to supplement OPSC s 54th Annual Convention and Exposition Syllabus 1152
8 Testing HIV Elisa Western Blot immunoassay quantitative and qualitative HIV 1 and 2 antibody differentiation Nucleic Acid Test HIV RNA PCR OPSC s 54th Annual Convention and Exposition Syllabus 1153
9 OPSC s 54th Annual Convention and Exposition Syllabus 1154
10 Acute Retroviral Syndrome maculopapular rash mucocutaneous ulceration headache lymphadenopathy myalgia/arthralgia anorexia/nausea/vomiting/diarrhea retro-orbital pain OPSC s 54th Annual Convention and Exposition Syllabus 1155
11 Treatment.. When to start: NOW What to start with: coming up How long to treat: Permanent OPSC s 54th Annual Convention and Exposition Syllabus 1156
12 OPSC s 54th Annual Convention and Exposition Syllabus 1157
13 Life Cycle and Interference nrtis NNRTIs PIs Integrase Strand Inhibitors Entry Inhibitors (Fuzeon, Selzentry) Transcription Inhibitors OPSC s 54th Annual Convention and Exposition Syllabus 1158
14 with permission from AidsMeds com OPSC s 54th Annual Convention and Exposition Syllabus 1159
15 OPSC s 54th Annual Convention and Exposition Syllabus 1160
16 Initial Antiretroviral Regimens. 2 nrtis + Int Inhib Tenofovir + Emtricitabine (Truvada) and Dolutegravir Abacavir + Lamivudine + Dolutegravir (Triumeq) Tenofovir + Emtricitabine + Elvitegravir/cobicistat (Stribild) 2 nrtis + NNRTI Tenofovir + Emtricitabine (Truvada) and Efavirenz. (Atripla) Abacavir + Lamivudine (Epzicom) and Efavirenz Tenofovir + Emtricitabine (Truvada) and Rilpivirine. (Complera) 2 nrtis + PI/r Tenofovir + Emtricitabine (Truvada) and Atazanavir Abacavir + Lamivudine (Epzicom) and Atazanavir Tenofovir + Emtricitabine (Truvada) and Darunavir (Prezista) OPSC s 54th Annual Convention and Exposition Syllabus 1161
17 Alternatives 2nRTIs plus InSTI Abacavir + Lamivudine (Epzicom) plus Raltegravir 2nRTIs plus NNRTI 2nRTIs plus PI 2nRTIs plus Nevirapine ** Abacavir + Lamivudine (Epzicom) plus Rilpilvirine 2nRTIs plus Atazanivir/colbicistat 2nRTIs plus Darunavir/colbicistat Abacavir/lamivudine (Epzicom) plus Darunavir OPSC s 54th Annual Convention and Exposition Syllabus 1162
18 OPSC s 54th Annual Convention and Exposition Syllabus 1163
19 OPSC s 54th Annual Convention and Exposition Syllabus 1164
20 Single Dose Therapy for HIV Infection Atripla Efavirenz + Tenofovir + Emtricitabine Complera Rilpivirine + Tenofovir + Emtricitabine Stribild Elvitegravir + Cobicistat + Tenofovir + Emtricitabine Triumeq Dolutegravir + Abacavir + Lamivudine OPSC s 54th Annual Convention and Exposition Syllabus 1165
21 Monitoring 200. re-evaluate. Viral load 4 weeks after starting med, then q 3 to 6 months if over 50, recheck. over Tcells every 3 to 6 months.. Average Genotype (Phenosense) testing in all new and virologic failure. and sure. Know when to switch meds: labs, clinical, options. Be clear OPSC s 54th Annual Convention and Exposition Syllabus 1166
22 Associated Disorders Opportunistic Infections Prophylaxis Pneumocystis jiroveci Sulfamethoxazole/trimethoprim Toxoplasma gondii Sulfamethoxazole/trimethoprim Mycobacterium avium complex Azithromycin Mycobacterium tuberculosis Isoniazid + pyridoxine Cryptococcus Fluconazole Cytomegalovirus Valganciclovir herpes simplex -- varicella zoster Acyclovir OPSC s 54th Annual Convention and Exposition Syllabus 1167
23 Cardiovascular and Metabolic Disorders Liver Disease Kidney Disease Cancers OPSC s 54th Annual Convention and Exposition Syllabus 1168
24 Interactions OPSC s 54th Annual Convention and Exposition Syllabus 1169
25 OPSC s 54th Annual Convention and Exposition Syllabus 1170
26 Vaccinations.. Immunizations Td/Tdap. Tetanus, diphtheria, acellular pertussis. every 10 years should have a T/dap booster Varicella vaccine (Varivax)is CONTRAINDICATED in patients with HIV who have less than 200 Tcells. Those with over 200 T cells should receive the vaccine Human Papillomavirus (HPV). All patients with HIV up to age 26. should receive 3 doses of HPV vaccine Zoster. Zostavax vaccine Pneumococcal vaccine naive HIV-infected adults should receive pneumococcal 13-valent conjugate vaccine first, followed by a dose of pneumococcal 23-polyvalent vaccine at least 8 weeks later. Boost every 5 years. OPSC s 54th Annual Convention and Exposition Syllabus 1171
27 Vaccinations.. Immunizations, cont d MMR, Measles, Mumps, Rubella vaccine. one or two doses at age 19 to 49. Booster at age +50. NO for less than 200 tcells Meningococcal vaccine. not a standardly administered vaccine to either healthy adults or to patients with HIV infection Hepatitis B vaccine (and Hepatitis A in combo administration).. check every 5 years for immunity. Hepatitis C vaccine.. Not yet available. OPSC s 54th Annual Convention and Exposition Syllabus 1172
28 PreP and PEP. Pre Exposure Prophylaxis I recommend for all patients who are having sex. Studies have shown a 60% decrease in new infection among those taking Truvada (Emtricitabine and Tenofovir). This is to be used in conjunction with condom use and safe sex. There are disconcordant couple studies which show no new infection. More to come. Renal check and HIV q 3 months or no refill. OPSC s 54th Annual Convention and Exposition Syllabus 1173
29 Post Exposure Prophylaxis Occupational: Do not delay; Test the source; Consider HIV-1 RNA of source; Include Hepatitis B testing; May discontinue if source confirmed negative. Know the patient and the source patient if possible. Risk-stratification. 72 hour window HIV testing at baseline, 6 weeks 12 weeks and 6 months. May consider HIV-1 RNA testing qualitative on day 6+. Numerous choices but primary is: Truvada(1/d) and Raltegravir (Isentress) (bid) Remember to watch and test for Hepatitis C OPSC s 54th Annual Convention and Exposition Syllabus 1174
30 more information InPractice.com is simply amazing. You will find everything there. AidsMeds.com is accurate and up to date and great for the professional and the patient. International AIDS Society.. you can find online CCO Clinical Care Options also online.. excellent information and credits too OPSC s 54th Annual Convention and Exposition Syllabus 1175
31 RETURN TO TABLE OF CONTENTS OPSC s 54th Annual Convention and Exposition Syllabus 1176
Sculpting a Better Regimen: The ART of HIV Medications
Sculpting a Better Regimen: The ART of HIV Medications Kelly Peddy, PharmD, MPA Clinical Pharmacy Specialist - Ambulatory Care Memorial Hospital of South Bend November 30, 2017 For HealthTrust Members
More informationHIV Management Update 2015
9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe
More informationNothing to disclose.
Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital HIV UPDATE FOR THE PRIMARY CARE PROVIDER Nothing to disclose. 1 Outline Epidemiology Screening / testing for HIV
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationExploring HIV in 2017: What a pharmacist needs to know
Exploring HIV in 2017: What a pharmacist needs to know Lifecycle of the HIV virus a. HIV spread through mucous membrane contact, damaged tissue contact, or blood contact with: blood, semen, rectal fluids,
More informationHIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
More informationHIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationPROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV
PROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV Madhuri Lad, DO, FACOI, AAHIVS Clinical Assistant Professor OSU Department of Internal Medicine OBJECTIVES Demographics Definitions Diagnosis
More informationAn HIV Update Jan Clark, PharmD Specialty Practice Pharmacist
An HIV Update - 2019 Jan Clark, PharmD Specialty Practice Pharmacist 2 The goal of this program is to provide a review and update of HIV care and to provide a forum for discussing the current local and
More informationFluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids
Supportive therapy Summary of interactions Table 1. Summary of potential interactions between antiretroviral agents and supportive therapy Interactions with enzyme inhibitors (protease inhibitors and elvitegravir/cobicistat)
More informationDidactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
More informationHIV Treatment Guidelines
HIV Treatment Guidelines Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Are Treatment Guidelines? Issued by variety of global and country-based
More informationClinical Education Initiative THE ROLE OF THE PRIMARY CARE CLINICIAN IN HIV CARE. Speaker: Antonia Urbina, MD
Clinical Education Initiative Support@ceitraining.org THE ROLE OF THE PRIMARY CARE CLINICIAN IN HIV CARE Speaker: Antonia Urbina, MD 2/1/2017 The Role of the Primary Care Clinician in HIV Care [video transcript]
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Antiretroviral Medications: What you need to know Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Associate Professor, Department of Pharmacy Practice Jefferson College of Pharmacy, Thomas Jefferson University
More informationThird Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily
Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages
More informationDidactic Series. HIV Drug-Drug Interactions: OTC and non-prescription medications. Kirsten B. Balano, PharmD UCSF School of Pharmacy February 26, 2015
Didactic Series HIV Drug-Drug Interactions: OTC and non-prescription medications Kirsten B. Balano, PharmD UCSF School of Pharmacy February 26, 2015 ACCREDITATION STATEMENT: University of California, San
More informationHIV medications HIV medication and schedule plan
Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with
More informationStarting Immediate Treatment for HIV-1
Starting Immediate Treatment for HIV-1 Ronald P. Hattis, MD, MPH Email: ronhattis@foundation.beyondaids.org Associate Prof. of Preventive Medicine, Loma Linda University Secretary, Beyond AIDS Foundation
More informationHIV Treatment Update. Objectives. Epidemiology 12/22/2015
HIV Treatment Update Monique Calil, Pharm.D. PGY-1 Resident Broward Health Medical Center Objectives Review antiretroviral therapy (ART) medications used for the treatment of HIV, including new combination
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationHIV IN OKLAHOMA MAKING A DIFFERENCE
HIV IN OKLAHOMA MAKING A DIFFERENCE Madhuri Lad, DO, FACOI, AAHIVS Assistant Program and Medical Director OSU Internal Medicine Specialty Services HIV Program Clinical Assistant Professor Rashes Demographics
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationtreatment passport 1
treatment passport 1 Why keep a treatment history? Keeping a short record of your treatment history can help in many ways. It can help you understand your health and treatment. It can help if your doctor
More informationGuidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters
Guidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationWOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /
More informationHIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship
HIV basics Katya Calvo Medical Director of Antimicrobial Stewardship Learning Objectives 1. Review of HIV epidemiology worldwide and locally 2. Review of recommendations on whom to screen 3. Work up of
More informationHIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014
Objectives HIV Update 2014 Jay Sizemore, MD, MPH Medical Director Chattanooga CARES Assistant Professor UTCOM Chattanooga 2October 2014 Review HIV epidemiology and screening/testing guidelines Discuss
More informationPREVENTION OF HIV IN THE TIMES OF PREP. Daniela Chiriboga, MD Florida Department of Health in Polk County
PREVENTION OF HIV IN THE TIMES OF PREP Daniela Chiriboga, MD Florida Department of Health in Polk County MAKING THE CASE FOR PREVENTION The Epidemic in Florida Population in 2014: 19.6 million (3 rd in
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationThe Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018
The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and
More informationClinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationANTIRETROVIRAL TREATMENTS (Part 1of
CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after
More informationHIV Update. Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine
HIV Update Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine Rates of Diagnoses of HIV Infection among Adults and Adolescents, 2012 United States and 6 Dependent
More informationClinicalGuidance May 2016
ClinicalGuidance May 2016 TABLE OF CONTENTS 1. PURPOSE AND OVERVIEW... 1 2. DIAGNOSIS AND REPORTING... 1 Indications for Testing for HIV... 1 Counseling of Inmates Prior to HIV Testing... 2 HIV SerologicalTesting
More informationThe ART of Antiretroviral Therapy in Critically-ill Patients with HIV
The ART of Antiretroviral Therapy in Critically-ill Patients with HIV Tyler Finocchio, PharmD, BCPS PGY2 Critical Care Pharmacy Resident Avera McKennan Hospital & University Health Center February 10 th,
More informationObjectives. HIV in the Trenches HIV Update for the Primary Care Provider, An Overview The HIV Continuum of Care.
1:30 2:30pm HIV Update SPEAKER Gordon Dickinson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Gordon Dickinson, MD, has no financial relationships
More informationResistance to Integrase Strand Transfer Inhibitors
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Resistance to Integrase Strand Transfer Inhibitors David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases
More informationcontinuing education for pharmacists
continuing education for pharmacists HIV/AIDS: Overview and Resources for Pharmacists Mona T. Thompson, R.Ph., PharmD Volume XXXIII, No. 9 Dr. Mona T. Thompson has no relevant financial relationships to
More informationTreatment and Care: Product portfolio
Treatment and Care: Product portfolio Dr Paula Munderi MRC/UVRI Uganda Research Unit on AIDS EDCTP Stakeholder Meeting on HIV/AIDS 3-4 September 2013 Summary Brief overview HIV Treatment Pipeline Key Questions
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationCLINICAL PEARLS OF NEW HIV MEDICATIONS PHARMACIST OBJECTIVES TECHNICIAN OBJECTIVES. At the end of this presentation pharmacists will be able to:
CLINICAL PEARLS OF NEW HIV MEDICATIONS Cindy Lou Zoellner, PharmD, BCPS Added Qualifications in Infectious Diseases Senior Clinical Pharmacy Specialist in HIV Parkland Health & Hospital System Volunteer
More informationMatters of the HAART: An Update on Current Treatment Options for HIV
Matters of the HAART: An Update on Current Treatment Options for HIV Jason Alegro, PharmD, BCPS Assistant Professor of Clinical Sciences, Roosevelt University Infectious Diseases Clinical Pharmacy Specialist,
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationReportback from the 2013 ICAAC in Denver, CO
Information, inspiration and advocacy for people with HIV/AIDS and hepatitis C p1 p3 p8 PrEP NEWS New tenofovir vaginal ring protects monkeys, PrEP uptake higher among women and young people. HIV CARE
More informationMidwestern Underwriting Conference 2016
UNDERWRITING HIV: THE FAIRY TALE HAS BECOME REALITY Midwestern Underwriting Conference 2016 Jean-Marc Fix, FSA, MAAA VP, R&D, Optimum Re Insurance Co. AGENDA Where are we with HIV? The risk The ideal case
More informationLondon Therapeu-c Tender Implementa-on: Guidance for Clinical Use. 14 January 2015
London Therapeu-c Tender Implementa-on: Guidance for Clinical Use 14 January 2015 Contents 2 3. General principles 4. Financial impact of therapeu-c tendering for branded ARVs 5. London ARV algorithm:
More informationCost impact of an HIV MDT for managing anti-retroviral switch
Cost impact of an HIV MDT for managing anti-retroviral switch 2016 ST4 Farnaz Dave Infectious Diseases & General Internal Medicine Mr Ian Sayers Specialist Infectious Diseases Pharmacist Dr Fahar Niazi
More informationEviplera: New First-Line Treatment Options for patients with HIV (own clinical experience in Izrael) Itsik Levy MD
Eviplera: New First-Line Treatment Options for patients with HIV (own clinical experience in Izrael) Itsik Levy MD Population: 8,000,000 Ethnic groups: 75% Jewish 20% Arabs 5% Others HCS PPC 3.5/1000 NPC
More information1/13/16. Updated April 2015
Bernadette Jakeman, PharmD, PhC, BCPS, AAHIVP Assistant Professor UNM College of Pharmacy bjakeman@salud.unm.edu Pharmacist objectives: 1. Summarize key updates to the DHHS treatment guidelines. 2. Identify
More informationThe ART of Managing Drug-Drug Interactions in Patients with HIV
The ART of Managing Drug-Drug Interactions in Patients with HIV Bradley L. Smith, Pharm.D. smith.bradley1@mayo.edu Pharmacy Grand Rounds December 19, 2017 2017 MFMER slide-1 Presentation Objectives Describe
More informationJonathan Cohn MD Wayne State University July 24,
Jonathan Cohn MD Wayne State University July 24, 2017 www.matecmichigan.org jcohn@med.wayne.edu Current HIV Test Sequence 4 th Generation Ag/Ab Combo > Differentiation Assay Abbott Architect Alere Determine
More informationNorthwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care
Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care www.nwaetc.org The Northwest AIDS Education and Training Center (NW AETC), located at the University
More informationRisk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf
Risk of HIV-1 low level viremia to treatment failure in the AREVIR-RESINA cohort in Germany Nadine Lübke Düsseldorf FDA Approval of antiretroviral drugs 1980-84 1985-89 1990-94 1995-99 2000-04 2005-09
More informationYear 2002 Paper two: Questions supplied by Jo 1
Year 2002 Paper two: Questions supplied by Jo 1 Question 9 A 37 year old man with known human immunodeficiency virus (HIV) infection for 10 years presents with severe renal colic for which he has no prior
More informationMedical Overview March 7, Nina Lambert, NP Inova Juniper Program
Medical Overview March 7, 2019 Nina Lambert, NP Inova Juniper Program Nina.lambert@inova.org Inova Juniper Program Sites Offering medical care, case management and mental health for youth and adults who
More informationUpdates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017
Mountain West AIDS Education and Training Center Updates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017 26 October 2017 Hillary
More informationTORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION
TGH - ambulatory rotation page 1 of 5 TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION SITE: Immunodeficiency Clinic, Toronto General Hospital, University Health Network Location: 13 th floor, Norman
More informationPurpose Methods Demographics of patients in the study Outcome. Efficacy Adverse Event. Limitation
ANDREW LEE Purpose Methods Demographics of patients in the study Outcome Efficacy Adverse Event Limitation Dolutegravir Integrase inhibitor Plasma half life 14hours Tivicay FDA (US)- 13 August 2013 50mg
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationClinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV positive adults and adolescents Reference: NHS England F03/P/b NHS England INFORMATION READER BOX Directorate Medical Commissioning
More informationINTEGRATING HIV INTO PRIMARY CARE
INTEGRATING HIV INTO PRIMARY CARE ADELERO ADEBAJO, MD, MPH, AAHIVS, FACP NO DISCLOSURE 1.2 million people in the United States are living with HIV infection and 1 in 5 are unaware of their infection.
More informationDoravirine vs. darunavir
From TreatmentUpdate 220 Doravirine vs. darunavir Doravirine is an experimental non-nuke that is undergoing phase III clinical trials. It is designed to be effective against most strains of HIV that are
More informationApproach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D.
Approach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D. Disclosures: grant support from Gilead, Roche, EBSCO Objectives Apply current guidelines to initial evaluation
More informationRECOMMENDED IMMUNIZATIONS
Recommended Immunization Schedule for Persons Aged 0 Through 6 Years United States 2010 1 2 4 6 12 15 18 19 23 2 3 4 6 Vaccine Age Birth month months months months months months months months years years
More informationHealthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020.
Appendix 1: Healthy People 2020 Immunization-related Objectives Healthy People provides science-based, 10-year national objectives for improving the health of all Americans. For three decades, Healthy
More informationActualización y Futuro en VIH
Actualización y Futuro en VIH Dr. Santiago Moreno Servicio de Enfermedades Infecciosas Hospital U. Ramón y Cajal. Universidad de Alcalá. IRYCIS. Madrid Agenda Control of the HIV-epidemic Coinfections Antiretroviral
More informationAppropriate Use & Safety Edits
Appropriate Use & Safety Edits Envolve Pharmacy Solutions provides a variety of safety edits to promote the use of the right medication, in the right patient, at the right time. These edits are routinely
More informationClinical Commissioning Policy Proposition: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents
Clinical Commissioning Policy Proposition: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents Reference: NHS England F03X08 First published: Month Year Prepared by NHS England Specialised
More informationDidactic Series. Update: 2012 HIV Treatment Guidelines. Daniel Lee, MD August 30, 2012
Didactic Series Update: 2012 HIV Treatment Guidelines Daniel Lee, MD August 30, 2012 ACCREDITATION STATEMENT: University of California, San Diego School of Medicine is accredited by the Accreditation Council
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationHIV for the Non-ID Pharmacist
Disclosures HIV for the Non-ID Pharmacist I have nothing to disclose at this time Carmen Faulkner-Fennell, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist--Infectious Diseases Greenville Hospital System
More informationClinical Commissioning Policy: Dolutegravir for treatment of HIV-1 infection (all ages) NHS England Reference: B06/P/a
Clinical Commissioning Policy: Dolutegravir for treatment of HIV-1 infection (all ages) NHS England Reference: B06/P/a 1 2 Clinical Commissioning Policy: Dolutegravir for treatment of HIV-1 infection (all
More informationMANAGEMENT OF HIV INFECTION
MANAGEMENT OF HIV INFECTION Federal Bureau of Prisons Clinical Guidance September 2018 Clinical guidance is made available to the public for informational purposes only. The Federal Bureau of Prisons (BOP)
More informationOctober 26-28: Training Day 1
Peer Linkage and Re-Engagement of HIV- Positive Women of Color October 26-28: Training Day 1 Peer Linkage and Re -Engagement of HIV - Positive Women of Color Convening Training Trainers Today: Alicia Downes
More informationWOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM
WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM ID LABEL HERE ---> VERSION DATE 10/01/07 - - - VISIT #: FORM COMPLETED BY: A1. DATE OF BLOOD DRAW: / / M D Y A2. Do you take
More informationALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS
ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS - 2014 Alabama s ADAP formulary offers a minimum of one medication from each HIV antiretroviral class approved by the U.S. Food and Drug Administration (FDA).
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationAppendix An Assessment Tool to Determine the Validity of Vaccine Doses
Appendix 4.4 - An Assessment Tool to Determine the Validity of Vaccine Doses Note: Refer to the Canadian Immunization Guide and New Brunswick (NB) immunization program directives for recommendations for
More informationPerinatal Care and Prevention. Jennifer Janelle, MD Assistant Professor of Medicine University of Florida at Gainesville
Perinatal Care and Prevention Jennifer Janelle, MD Assistant Professor of Medicine University of Florida at Gainesville Objectives Develop patient centered, team based, treatment and delivery plans to
More informationWoman with Cervicitis
1 Infectious Diseases Update David Spach, MD Last Updated: January 30, 2015 Infectious Diseases 2015 Update STDs Hepatitis C Virus HIV Chikungunya Virus Ebola Virus Sexually Transmitted Diseases 2 Woman
More informationHIV A 2017 Update Bill Rooney MD SCOR Global Life
NHOLUA November 14, 2017 HIV A 2017 Update Bill Rooney MD SCOR Global Life Agenda 1 2 3 4 5 The Immune System HIV the illness Prevalence Diagnosis Natural Course Treatment A look at 100 HIV patients Changing
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)
More informationClinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV infection (all ages) Reference: NHS England F03/P/b
Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV infection (all ages) Reference: NHS England F03/P/b NHS England INFORMATION READER BOX Directorate Medical Commissioning
More informationAction Item for 2019 Review of Tool. Maintain (add include oral cavity) Maintain. Archive. Archive. 12 creatinine)
NEWLY DIAGNOSED/ NEW TO CARE PROGRAM SITE: REVIEWER(S): REVIEW DATE: CORE SERVICES Outpatient/Ambulatory Health Services Tool - 2018 (OLD) SECTION 1: CHART REVIEW Review for newly diagnosed HIV patients
More informationInformation, inspiration and advocacy for people with HIV/AIDS and hepatitis C
Information, inspiration and advocacy for people with HIV/AIDS and hepatitis C p1 p5 p6 p7 HIV CARE NEWS New drugs: dolutegravir, MK-1439, cenicriviroc, and HIV and heart health. HIV PrEP NEWS Disappointing
More informationHIV/AIDS Update 2007
HIV/AIDS Update 2007 Joanne J. Orrick, Pharm.D., BCPS Clinical Assistant Professor University of Florida Faculty, Florida/Caribbean AIDS Education and Training Center orricjj@ufl.edu www.faetc.org orricjj@ufl.edu
More informationAn International Antiviral Society-USA
Doug Campos-Outcalt, MD, MPA University of Arizona, Phoenix dougco@email.arizona. edu A look at new guidelines for HIV treatment and prevention Start antiretroviral therapy as soon as possible after HIV
More informationApproach for the Newly Diagnosed HIV Positive Patient
Approach for the Newly Diagnosed HIV Positive Patient Jason E. Farley, PhD, MPH, ANP-BC, FAAN, AACRN Associate Professor & NP, Johns Hopkins University School of Nursing & Medicine Director, AETC Adult-Gerontology
More informationBlood-Borne Pathogens and Post-Exposure Prophylaxis
Blood-Borne Pathogens and Post-Exposure Prophylaxis Christopher Behrens MD Northwest Association of Occupational and Environmental Medicine October 2017 with thanks to Shireesha Dhanireddy MD Disclosures
More informationANNUAL HEALTH SCREENINGS AND IMMUNIZATIONS GUIDE MEN WOMEN ALL ADULTS CHILDREN
AND IMMUNIZATIONS GUIDE MEN WOMEN ALL ADULTS CHILDREN MEN PROSTATE CANCER Testicular exam Age 18+ PSA test Ages 50-75, based on risk WOMEN BREAST CANCER Self breast exam Monthly Clinical breast exam Annually
More informationSFAF CLINICAL PROTOCOLS
SFAF CLINICAL PROTOCOLS Page 1 of Supersedes Date: December 31, 2016 Original Date: August 20, 2014 Version: 03 Policy Section: Patient Care Non-Occupational Post Exposure Prophylaxis Program Back ground:
More informationStarting Immediate Treatment for HIV-1
Starting Immediate Treatment for HIV-1 Ronald P. Hattis, MD, MPH Email: ronhattis@beyondaids.org Associate Prof. of Preventive Medicine, Loma Linda University Secretary, Beyond AIDS Foundation November
More informationMedication Errors Focus on the HIV-Infected Patient
Medication Errors Focus on the HIV-Infected Patient Nimish Patel, Pharm.D., Ph.D., AAHIVP Associate Professor Albany College of Pharmacy & Health Sciences I do not have any conflict of interest in relation
More informationINTEGRASE INHIBITOR (INI) RESISTANCE IN HIV- POSITIVE PATIENTS UNDERGOING ROUTINE TESTING
INTEGRASE INHIBITOR (INI) RESISTANCE IN HIV- POSITIVE PATIENTS UNDERGOING ROUTINE TESTING Dr. Danni Kirwan ID/Microbiology SpR St. George s Hospital, London ARV initiation in treatment-naïve patients BHIVA,
More informationSOUTH FLORIDA SE AIDS EDUCATION & TRAINING CENTER. HIV and Oral Health in the Era of Antiretroviral Therapy
SOUTH FLORIDA SE AIDS EDUCATION & TRAINING CENTER HIV and Oral Health in the Era of Antiretroviral Therapy SOUTH FLORIDA SE AIDS EDUCATION & TRAINING CENTER Mark Schweizer, DDS MPH Director of Development
More informationBritish HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2
British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2 Systematic literature search 2.1 Questions and PICO criteria Data bases: Medline,
More information